Literature DB >> 11558706

The link between gross profitability and pharmaceutical R&D spending.

F M Scherer1.   

Abstract

Mesh：

Year:  2001        PMID： 11558706     DOI： 10.1377/hlthaff.20.5.216

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN： 0278-2715            Impact factor:   6.301


× No keyword cloud information.
  14 in total

1.  Returns on research and development for 1990s new drug introductions.

Authors:  Henry Grabowski; John Vernon; Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Setting prices for new vaccines (in advance).

Authors:  Thomas G McGuire
Journal:  Int J Health Care Finance Econ       Date:  2003-09

3.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

4.  Evergreening: a common practice to protect new drugs.

Authors:  Kate S Gaudry
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

5.  Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.

Authors:  John A Vernon; Scott H Shortenhaus; Mark H Mayer; Albert J Allen; Joseph H Golec
Journal:  Paediatr Drugs       Date:  2012-10-01       Impact factor: 3.022

Review 6.  Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.

Authors:  Henry Grabowski
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  On international cost-sharing of pharmaceutical R&D.

Authors:  Pedro Pita Barros; Xavier Martinez-Giralt
Journal:  Int J Health Care Finance Econ       Date:  2008-06-19

8.  The determinants of cost-effectiveness potential: an historical perspective on lipid-lowering therapies.

Authors:  Rodrigo Refoios Camejo; Clare McGrath; Marisa Miraldo; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

9.  Communication Strategies Must Be Tailored to a Medication's Targeted Population: Lessons from the Case of BiDil.

Authors:  Chamika Hawkins-Taylor; Angeline M Carlson
Journal:  Am Health Drug Benefits       Date:  2013-09

10.  Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development.

Authors:  Margaret E Blume-Kohout; Neeraj Sood
Journal:  J Public Econ       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.